We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

Cava gave light guidance late Tuesday after missing lofty earnings expectations for the fourth quarter. Cava stock extended its losing streak on Wednesday.Sweetgreen follows late Wednesday. Sweetgreen ...

Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Is your hair parting like the Red Sea? A few extra chunks of hair blocking the tub drain lately? Nobody wants to look for the ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.